Papillary thyroid cancer (PTC) also called papillary carcinoma is one of the most common type of thyroid cancer and it is most curable among other cancers. Follicular cancer, medullary cancer, and anaplastic cancer are other types of thyroid cancers. The prevalence rate of papillary thyroid cancer is 0.5-10 per 100,000 population. Papillary thyroid carcinoma presents as asymptomatic thyroid nodules, increasing the size of nodule in patient is the primary symptom for this disease. Cough, dyspnea and dysphagia are the severe stage symptoms of papillary thyroid cancer and lump or swelling in the neck parts are the physical symptoms of the papillary thyroid cancer. Age, gender and exposure to radiation affect the risk of papillary thyroid cancer. Itis more common in women than in men, and often occurs before age 45. People who have been exposed to large amounts of radiation, or who have had radiation therapy for medical problems in the head and neck have a more chance of getting thyroid cancer.
To treat papillary thyroid cancer various methods are available which include surgical procedure, iodine therapy, thyroxin treatment and external radiotherapy. In surgical procedure, surgeon removes affected tissue from the neck. Iodine therapy is given to the patient post operatively to destroy normal thyroid remnants. External radiotherapy is indicated for the patients with age group 45 years and above.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1659
The growth of thyroid tumor cells are controlled by thyrotropin and is inhibited by thyroxin, inhibition of thyrotropin with thyroxin increase the recurrence of survival rates. The most commonly used drugs in the treatment of papillary thyroid cancer are levothyroxine and radioiodine and antineoplastic agents such as cisplatin, doxorubicin and these drugs are used after the surgery and radiation therapy.
Papillary Thyroid Cancer Market has been classified on the basis of treatment and end user.
Papillary Thyroid Cancer by Treatment
- Iodine Therapy
- Thyroxin Treatment
- External Radiotherapy
Papillary Thyroid Cancer by End User
- Oncology Centres
- Hospital Pharmacies
- Retail Pharmacies
In 2015, According to American Cancer Society (ACS), thyroid cancer accounts 47,230 in women and 15,220 in men in the U.S. and the incidence rate and mortality rate of thyroid cancer is high in women than in men. Thus, the increasing prevalence and incidence rate of thyroid cancers is expected to drive the overall papillary thyroid cancer. Increasing awareness about the cancer disease, raising government funds and reimbursement policies from Medicare and Medicaid are the key factors which are expected to propel the overall papillary thyroid cancer treatment market. The cost of the drugs and procedures is one of the major restraint for papillary thyroid cancer treatment market.
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1659
Depending on geographic region, papillary thyroid cancer market is segmented into seven key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is estimated to contribute maximum revenue share in the global market of Papillary Thyroid Cancer followed by Europe. Asia Pacific regions is expected to grow at a higher growth rate owing to high occurrence of cancer diseases. Middle East & Africa is expected to show a healthy growth rate in the forecast period
Key players of papillary thyroid cancer market are Mylan pharmaceuticals Inc., Baxter International Inc., Alara Pharmaceutical Corporation, Abbott laboratories, Bristol Myers co., Teva parenteral medicines Inc., Jerome Stevens Pharmaceuticals Inc., and App pharmaceuticals llc.